Newsroom

CSL Behring Announces Professor Heimburger Awards in Advance of ISTH 2020 Virtual Congress

KING OF PRUSSIA, Pa. • Five coagulation researchers named this year’s recipients • Professor Heimburger Awards and ISTH…

In Fight Against COVID-19, CSL Behring Begins Trial to Evaluate Monoclonal Antibody (CSL312) for Respiratory Distress

KING OF PRUSSIA, Pa. - Phase II placebo-controlled study will assess the safety and efficacy of CSL312 for the treatment…

COVID-19 Update

CSL continues to provide medicines to patients around the world.

CSL Behring Agrees to Acquire Novel Late-Stage Gene Therapy Candidate for Hemophilia B Patients from uniQure

KING of PRUSSIA, Pa. • Unique gene therapy has the potential to be one of the first to market treatments to provide potent…

Yi Deng and Bill Mezzanotte Elected to University City Science Center Board of Directors

PHILADELPHIA

CSL Behring to Attend and Sponsor World Federation of Hemophilia First Ever Virtual Summit

King of Prussia, Pa Global bleeding disorders community will connect and discuss treatment advances June 14-19, 2020

CSL Behring to Acquire Biotech Company Vitaeris

KING OF PRUSSIA, Pa • Builds on CSL Behring’s promise and commitment to the transplant community • Deal accelerates the a…

CSL Behring Presents Results for Garadacimab as Preventive Treatment in Hereditary Angioedema

HATTERSHEIM, Germany Investigational Monoclonal Antibody Granted U.S. FDA Orphan Drug Designation